 1. Known infection with HIV, HCV, or HBV. This information will be obtained verbally from the patient. 2. If female, active pregnancy or breast-feeding or plans to become pregnant during study participation. 3. Chronic medical conditions that cause immunodeficiency or that require medications which could alter immune function such as immunosuppressants and immunoenhancers. 4. Have any medical disease or condition that, in the opinion of the site principal investigator or appropriate sub-investigator, is a contraindication to study participation. This includes any chronic medical disease or condition, defined as persisting 3 months defined as 90 days or longer, that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subjects successful completion of this study 5. Have an acute illness, as determined by the site principal investigator or appropriate sub-investigator, within 72 hours prior to study vaccination. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site principal investigator or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol. 6. Persons taking anticoagulants, long-term aspirin therapy, or long-term systemic steroids greater than 3 months in the past 12 months and any within 30 days. 7. Have known hypersensitivity or allergy to eggs, egg or chicken protein or other components of the study vaccine; 8. Have a known latex allergy; 9. Have a history of severe reactions following previous immunization with licensed influenza virus vaccines 10. Have a history of Guillain-Barre syndrome 11.Subjects who had or are suspected to have had an influenza infection in the current influenza season 12. Subjects who, at screening, have abnormal vital signs andor physical exam, including a temperature 38.0 C, Systolic blood pressure 90 or 160 mmHg, pulse 60 or 110 beats per minute, new rash, signs of infection. 13. Subjects who have already received the seasonal influenza vaccine in the current influenza vaccination season. 